Tests

The Pentagon and the Federal Aviation Administration agreed to conduct anti-drone laser tests in New Mexico after the military’s deployment of the lasers led the FAA to suddenly close airspace in Texas twice in the last month.

The newly announced testing was being carried out to “specifically address FAA safety concerns,” the military said Friday in a statement. It was to take place over the weekend at the White Sands Missile Range in New Mexico.

Lawmakers were concerned about an apparent lack of coordination after the Pentagon allowed U.S. Customs and Border Protection to use an anti-drone laser in early February without notifying the FAA. The federal agency that ensures safety in the skies decided to close the airspace over El Paso for a few hours, stranding travelers.

The Trump administration said it was working to halt an incursion by Mexican cartel drones, which are not uncommon along the southern border.

On Feb. 26 the U.S. military said it used the laser to shoot down a “seemingly threatening” drone flying near the U.S.-Mexico border. It turned out the drone belonged to Customs and Border Protection, lawmakers said.

The incident led the FAA to close the airspace around Ft. Hancock, about 50 miles southeast of El Paso.

“We appreciate the coordination with the Department of War to help ensure public safety,” the FAA said of the testing in a separate statement, referring to the Department of Defense. “The FAA and DOW are working with interagency partners to address emerging threats posed by unmanned aircraft systems while maintaining the safety of the National Airspace System.”

The military is required to formally notify the FAA when it takes any counter-drone action inside U.S. airspace.

Sen. Tammy Duckworth (D-Ill.), the ranking member on the Senate’s aviation subcommittee, previously called for an independent investigation after the two February incidents.

Ding writes for the Associated Press.

Kim Jong Un supervised the launch of sea-to-surface ‘strategic cruise missiles’ from country’s new naval destroyer.

North Korean leader Kim Jong Un has overseen the test-firing of “strategic cruise missiles” from a new 5,000-tonne naval destroyer before the vessel’s official commissioning, according to state media.

Kim supervised the launch of sea-to-surface missiles from the destroyer Choe Hyon on Wednesday, assessing the test as a “core” element of the new warship’s capabilities, which he described as a “new symbol of sea defence” for his country.

Calling for the production of more warships of a similar class or better, Kim said his navy’s adoption of nuclear weapons was making progress.

“Our Navy’s forces for attacking from under and above water will grow rapidly. The arming of the Navy with nuclear weapons is making satisfactory progress,” Kim said at the Nampo Shipyard in the west of the country, according to North Korea’s official Korean Central News Agency (KCNA).

“All these successes constitute a radical change in defending our maritime sovereignty, something that we have not achieved for half a century,” he said.

South Korea’s official Yonhap news agency noted that North Korea uses references to “strategic” weapons to indicate they could have nuclear capabilities.

According to KCNA, over a two-day visit to the shipyard, spanning Tuesday and Wednesday, Kim inspected the Choe Hyon, the lead vessel in a new series of 5,000-tonne “Choe Hyon-class” destroyers currently under construction in North Korea.

‘Wage a more active and persistent struggle’

In May 2025, North Korea’s ambitious naval modernisation programme suffered a major setback when a second Choe Hyon-class destroyer capsized during a botched side-launch ceremony at Chongjin Shipyard, an incident witnessed by the Korean leader.

Later, and in a rare admission of failure, KCNA reported that a launch mechanism malfunction caused the stern of the 5,000-tonne destroyer to slide prematurely into the water. The accident crushed parts of the hull and left the bow stranded on the shipway.

At the time, Kim characterised the launch failure as a “criminal act”, blaming the incident on “absolute carelessness” and “irresponsibility” across multiple state institutions.

This week’s missile tests come after the North Korean leader pledged in late February to lift living standards as he opened a rare congress of the governing Workers’ Party, held once every five years.

Kim told the congress that the ruling party was “faced with heavy and urgent historic tasks of boosting economic construction and the people’s standard of living”.

“This requires us to wage a more active and persistent struggle without allowing even a moment’s standstill or stagnation,” he said.

North Korea has prioritised nuclear weapons development and military strength above all else, claiming that it must be militarily strong to resist pressure from the United States and its ally, South Korea.

Since taking power in late 2011, Kim has maintained the military as a core priority while simultaneously emphasising economic strengthening to address the country’s chronic impoverishment.

ST. PAUL, Minin., Feb. 27 (UPI) — A team of U.S.-based scientists say they have developed a model using a “biological clock” to predict — with just a simple blood test — when someone is likely to develop symptoms of Alzheimer’s disease.

The results of a study published this month in the journal Nature Medicine demonstrate how, by measuring blood plasma levels of a protein in people who are not yet impaired by Alzheimer’s symptoms, researchers can predict when cognitive decline will begin within a margin of three to four years.

While there is no single, stand-alone test to diagnose Alzheimer’s today, the new method works by leveraging how levels of the protein “p-tau217” in the blood closely reflect how much amyloid plaque has built up in the brain over time. This provides doctors with a “clock” that points to when a patient may begin to experience symptoms.

Amyloid buildup in the brain may begin up to 20 years before a person starts to experience symptoms of memory and thinking issues. The plaques are a key pathological hallmark and contributing factor in Alzheimer’s disease, and, much like looking at the rings of a tree, p-tau217 levels can reveal the age of the buildup.

The authors, based at the Washington University School of Medicine in St. Louis, say their new blood test method will have immediate applications in ongoing clinical trials seeking answers to the vexing questions about what causes and what can prevent Alzheimer’s and dementia, which affect more than 7 million Americans at an estimated cost of nearly $400 billion in 2025.

Eventually, with further refinement, researchers hope the blood test could one day be used in clinical settings to easily and quickly provide predictions about the timeline of symptom onset for individual patients. The only feasible ways of doing so now are through costly brain imaging scans and invasive spinal fluid tests.

The study was part of a project headed by the Foundation for the National Institutes of Health Biomarkers Consortium, a public-private charitable partnership established by Congress in 1990 whose roster includes schools such as Washington University, life science companies including Johnson & Johnson and the Alzheimer’s Association.

Dr. Suzanne Schindler, senior author of the study and associate professor in the WashU Medicine Department of Neurology, said that while current blood tests for p-tau217 are already capable of identifying cognitively unimpaired people who might develop Alzheimer’s symptoms, they have no ability to estimate when.

Thus, they are used only for research studies and clinical trials due to legal and ethical considerations, such as the risk of causing undue stress from uncertain results.

“Our study, however, suggests it’s possible to predict when symptoms might develop using blood p-tau217,” she told UPI. “The prediction is very rough and so is still only useful in research or trials.

“We believe these predictions can be refined, but it’s unclear if they’ll become reliable enough for individual guidance without more invasive tests like spinal fluid analysis,” she cautioned.

Still, the potential of uses of the blood test are immediate when it comes to Alzheimer’s research. For instance, they could allow clinical trials of potentially preventive treatments to be performed within a shorter time period.

“Clinical trials are currently underway that are treating cognitively unimpaired individuals who test positive for blood p-tau217,” Schindler noted. “We must wait to see if these treatments delay or prevent symptom onset, but I’m hopeful based on our understanding of the disease’s biology.”

Beyond clinical trials, the blood test will aid broader Alzheimer’s research “by linking p-tau217 levels to specific brain changes, helping us disentangle whether those changes are driving cognitive impairment amid its overall complexity,” she added.

The new study “provides evidence that plasma p‑tau217 may be a reliable tool for estimating the future onset of Alzheimer’s disease symptoms,” agreed Rebecca Edelmayer, vice president of scientific engagement for the Alzheimer’s Association.

“This could transform how researchers design clinical trials and, eventually, how clinicians identify people at highest risk for cognitive decline associated with Alzheimer’s years before decline begins,” she told UPI.

While the blood test method represents a “very intriguing discovery,” it’s important to note it is not yet ready for everyday use by doctors or patients, Edelmayer cautioned, noting that its three- to four-year margin of error effectively rules out its utility for individual decision-making.

Broadly speaking, blood tests are not yet recommended for cognitively unimpaired individuals outside research settings, but even so, “this finding is an important research step because a blood test is generally much less expensive and easier to administer than a brain scan or spinal‑fluid test,” she said.

“In the future, it could help doctors and researchers identify people who may benefit from early treatments, and make clinical trials for new Alzheimer’s therapies run faster and more efficiently.”

The possibility of making a difference in the long-running battle against one of the most feared and intractable diseases in the world holds a special meaning for Schindler.

“As a memory specialist, I’ve diagnosed over 1,000 people with Alzheimer’s and witnessed firsthand its devastating effects on patients and families,” she said. “These results make me hopeful, and it’s rewarding to think this research could improve diagnosis and treatment of Alzheimer’s.”